Charlotte Hill, Yihua Wang. Autophagy in pulmonary fibrosis: friend or foe?. [J]. Genes & Diseases 9(6).(2022)
DOI:
Charlotte Hill, Yihua Wang. Autophagy in pulmonary fibrosis: friend or foe?. [J]. Genes & Diseases 9(6).(2022) DOI: 10.1016/j.gendis.2021.09.008.
Autophagy in pulmonary fibrosis: friend or foe?
摘要
Abstract
utophagy is an evolutionarily conserved process where long-lived and damaged organelles are degraded. Autophagy has been widely associated with several ageing-process as well in diseases such as neurodegeneration
cancer and fibrosis
and is now being utilised as a target in these diseases. Idiopathic pulmonary fibrosis (IPF) is a progressive
interstitial lung disease with limited treatment options available. It is characterised by abnormal extracellular matrix (ECM) deposition by activated myofibroblasts. It is understood that repetitive micro-injuries to aged-alveolar epithelium combined with genetic factors drive the disease. Several groups have demonstrated that autophagy is altered in IPF although whether autophagy has a protective effect or not is yet to be determined. Autophagy has also been shown to influence many other processes including epithelial-mesenchymal transition (EMT) and endothelial-mesenchymal transition (EndMT) which are known to be key in the pathogenesis of IPF. In this review
we summarise the findings of evidence of altered autophagy in IPF lungs
as well as examine its roles within lung fibrosis. Given these findings
together with the growing use of autophagy manipulation in a clinical setting
this is an exciting area for further research in the study of lung fibrosis.
FGF21-mediated autophagy: Remodeling the homeostasis in response to stress in liver diseases
LKB1 depletion-mediated epithelial–mesenchymal transition induces fibroblast activation in lung fibrosis
Autophagy-related lncRNAs in tumor progression and drug resistance: A double-edged sword
IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53
A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis
Related Author
Wei Shen
Modan Yang
Hao Chen
Chiyu He
Huigang Li
Xinyu Yang
Jianyong Zhuo
Zuyuan Lin
Related Institution
Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
The Institute for Organ Repair and Regenerative Medicine of Hangzhou
Institute of Organ Transplantation, Zhejiang University
Zhejiang University School of Medicine
National Center for Healthcare Quality Management in Liver Transplant